Hege Enger

Hege Enger

Auto-generated profile, based on publicly available information

Hege Enger

The Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MBMette Damkjær Bartels
Mette Damkjær Bartels
PWP. Worning
P. Worning
LAL.P. Andersen
L.P. Andersen
MBM. Bes
M. Bes
HEH. Enger
H. Enger
HWHenrik Westh
Henrik Westh

4 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PEPetter Elstrøm
Petter Elstrøm
EAElisabeth Astrup
Elisabeth Astrup
KHKristin Hegstad
Kristin Hegstad
ØSØrjan Samuelsen
Ørjan Samuelsen
HEHege Enger
Hege Enger
OKOliver Kacelnik
Oliver Kacelnik
Scandinavian countries have traditionally had a low prevalence of resistant organisms, but have in recent years experienced a change in their epidemiology. We aim to describe the epidemiology of carbapenemase-producing organisms (CPOs), vancomycin-resistant enterococci (VRE) and methicillin-resistant S. aureus (MRSA) in Norway, measure the importance of infections contracted abroad, and assess the morbidity and mortality associated with these resistant bacteria in Norway. We used data from the Norwegian surveillance system for communicable diseases covering all findings of the selected resistant bacteria including both infections and colonisation, in the period 2006–2017. Annual trends were assessed using negative binomial regression. For MRSA, we were able to calculate the Morisita-Horn index and transmission numbers following importation in order to assess the effect this had on further domestic transmission. The incidence rates (per 100,000 personyears) of the three groups of resistant bacteria have increased during the period. In 2017 the incidence rates were 0.82 for CPOs, 7.09 for VRE and 43.8 for MRSA. 81% of CPO cases were diagnosed in hospitals, but 73% were infected abroad. Most VRE cases were infected in Norwegian hospitals, 85% were associated with hospitals outbreaks. MRSA was predominantly diagnosed in the community, only 21% were diagnosed in hospitals. Of all MRSA cases, 35% were infected in other countries. Most MRSA spa-types were not identified again after introduction, resulting in a transmission of MRSA equivalent to a mean of 0.30 persons infected from each spa-type identified (range: 0–22). The proportion of infections among all notified cases within each diagnose was 44% for MRSA, 9% for VRE and 45% for CPOs. Among persons notified with bacteraemia, the 30 days all-cause mortality were 20%, 16% and 50% for MRSA, VRE and CPOs respectively. The incidence rates of CPOs, VRE and MRSA in Norway are low, but increasing. The continuing increase of notified resistant bacteria highlights the need for a revision of existing infection prevention and control guidelines.

26 January 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
VBValérie O. Baede
Valérie O. Baede
Michael Z. DavidMichael Z. David
Michael Z. David
AAArjana Tambic Andrasevic
Arjana Tambic Andrasevic
DBDominique S. Blanc
Dominique S. Blanc
MBMichael Borg
Michael Borg
MVMargreet C. Vos
Margreet C. Vos
Multinational surveillance programmes for methicillin-resistant Staphylococcus aureus (MRSA) are dependent on national structures for data collection. This study aimed to capture the diversity of national MRSA surveillance programmes and to propose a framework for harmonisation of MRSA surveillance. The International Society of Antimicrobial Chemotherapy (ISAC) MRSA Working Group conducted a structured survey on MRSA surveillance programmes and organised a webinar to discuss the programmes' strengths and challenges as well as guidelines for harmonisation. Completed surveys represented 24 MRSA surveillance programmes in 16 countries. Several countries reported separate epidemiological and microbiological surveillance. Informing clinicians and national policy-makers were the most common purposes of surveillance. Surveillance of bloodstream infections (BSIs) was present in all programmes. Other invasive infections were often included. Three countries reported active surveillance of MRSA carriage. Methodology and reporting of antimicrobial susceptibility, virulence factors, molecular genotyping and epidemiological metadata varied greatly. Current MRSA surveillance programmes rely upon heterogeneous data collection systems, which hampers international epidemiological monitoring and research. To harmonise MRSA surveillance, we suggest improving the integration of microbiological and epidemiological data, implementation of central biobanks for MRSA isolate collection, and inclusion of a representative sample of skin and soft-tissue infection cases in addition to all BSI cases.

23 October 2021 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
HEHege Enger
Hege Enger
KLKjersti Wik Larssen
Kjersti Wik Larssen
EDElise Størvold Damås
Elise Størvold Damås
HAHege Vangstein Aamot
Hege Vangstein Aamot
ABAnita Blomfeldt
Anita Blomfeldt
CÅChristina Gabrielsen Ås
Christina Gabrielsen Ås
The purpose of this study was to investigate the epidemiological, molecular, and clinical characteristics of MRSA t304/ST8 and t304/ST6 in Norway from 2008 to 2016. Clinical and epidemiological data were collected for each case included in the study. Strains were characterized by PCR, spa typing, antimicrobial susceptibility testing, and whole genome sequencing. The overall number of cases of MRSA t304 increased from 27 in 2008 to 203 in 2016. Most MRSA t304/ST8 cases were defined as HA-MRSA (89.9%) and diagnosed in persons with Norwegian background, many of them living in nursing homes (62.3%). The number of t304/ST8 cases declined throughout the study period and it has not been reported in Norway since 2014. The increasing MRSA t304/ST6 genotype has mainly been introduced to Norway by immigration from the Middle East, but also from other parts of the world. The t304/ST6 clone is mostly classified as CA-MRSA (75.1%), does not seem to cause serious infections, is not multi-resistant, and has not yet caused outbreaks in Norway. This study provides an example of two MRSA clones with the same spa type found in different epidemiological settings. This is very unusual, but still a reminder that spa typing in some cases may have insufficient discriminatory power for surveillance of MRSA. Our results highlight the importance of active surveillance and characterization of emerging MRSA clones with high potential for spread in the community, which may potentially cause outbreaks in healthcare facilities.

17 July 2025 in Eurosurveillance
Verified
Journal Article
Open access
LRLouise Roer
Louise Roer
NYNicolas Yin
Nicolas Yin
ODOlivier Denis
Olivier Denis
KVKaruna Ew Vendrik
Karuna Ew Vendrik
RZRomy Zwittink
Romy Zwittink
APAndreas Petersen
Andreas Petersen
We describe the genetic characteristics of a fusidic acid- and meticillin-resistant Staphylococcus aureus (MRSA) clone widespread in Europe, based on whole genome sequences from 317 isolates. The clone is causing impetigo and other skin and soft tissue infections, primarily in young children. Comparison with publicly available S. aureus ST121 sequences showed that the clone is clearly distinct from previously described ST121 clones. European and other international readers should be aware of the emergence of this community-acquired MRSA clone.